ReviewWorld journal of diabetes2017
Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia.
Review in World journal of diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Pooled it
- Obesity and risk of age-related eye diseases: a systematic review of prospective population-based studies.International journal of obesity (2005) · 2021Pooled it
- Metabolic Syndrome Predisposes Ossabaw Minipig Retina to an Early Neurodegenerative Milieu.Cells · 2026Article
- Assessment of retinal and hearing impairments related to microvascular dysfunction in metabolic syndrome.Northern clinics of Istanbul · 2026Article
- The Effect of Curcumin Plus Piperine on Mental Health Status, Sleep Quality, and Anthropometric Indices in Patients with Non-Proliferative Diabetic Retinopathy: A Randomized Double-Blind Placebo-Controlled Trial.International journal of preventive medicine · 2026Article
- The Role of Resistin in Macrovascular and Microvascular Complications of Type 2 Diabetes.Life (Basel, Switzerland) · 2025Review
- Association of Steatotic Liver Disease with Retinal Vascular Occlusion: The Influence of Obesity in a Large Health Screening Cohort.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- New Markers for the Assessment of Microvascular Complications in Patients with Metabolic Syndrome.Metabolites · 2025Review
- Severity of diabetic retinopathy severity with renal function and body fat in type 2 diabetes mellitus: A hospital-based cross-sectional study in India.Bioinformation · 2025Article
- Association between weight-adjusted-waist index and retinopathy among American adults: a cross-sectional study and mediation analysis.Frontiers in nutrition · 2025Article
- Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease.Medicina (Kaunas, Lithuania) · 2024Review
- Determination of osteopontin in monitoring retinal damage in metabolic syndrome.International journal of experimental pathology · 2024Article
- A Systematic Review of Metabolic Syndrome: Key Correlated Pathologies and Non-Invasive Diagnostic Approaches.Journal of clinical medicine · 2024Review
- Cardiovascular Risk Factors as Independent Predictors of Diabetic Retinopathy in Type II Diabetes Mellitus: The Development of a Predictive Model.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Quantifying physical activity, physical education and active travel in children and adolescents with visual Impairments.Heliyon · 2024Article
- Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy.International journal of pharmaceutics: X · 2024Article
- Obesity, body fat distribution and eye diseases.Eating and weight disorders : EWD · 2024Review
- The Metabolic Syndrome, a Human Disease.International journal of molecular sciences · 2024Review
- AMPK and Beyond: The Signaling Network Controlling RabGAPs and Contraction-Mediated Glucose Uptake in Skeletal Muscle.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is the most feared ocular manifestation of diabetes. DR is characterized by progressive retinal damage that may eventually result in blindness. Clinically, this blindness is caused by progressive damage to the retinal microvasculature, which leads to ischemia, retinal swelling, and neovascularization. Retinopathy is associated with both type 1 and type 2 diabetes, with DR being the leading cause of new onset blindness in United States adults. Despite this strong association with diabetes, it must be noted that the development of retinopathy lesions is multifactorial and may occur in individuals without an established history of diabetes. Metabolic syndrome is a multifactorial condition of central obesity, hypertriglyceridemia, dyslipidemia, hypertension, fasting hyperglycemia, and insulin resistance. Although several studies examined the individual components observed in the metabolic syndrome in relation to the development of DR, there is conflicting data as to the association of the metabolic syndrome with the development of retinopathy lesions in non-diabetic subjects. This review will summarize the current literature on the evidence of the metabolic syndrome on retinopathy in subjects with and without an established history of diabetes. This review will also discuss some of the mechanisms through which metabolic syndrome can contribute to the development of retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.